The UK Medicines and Healthcare products Regulatory Agency (MHRA) has announced approval of a new oral drug for treating moderate to severe plaque psoriasis — a chronic autoimmune skin disease characterized by red, scaly patches on the body. The new medication is intended for patients who have not benefited from other systemic therapies or for whom such therapies are contraindicated. Approval of the drug expands the range of treatment options available to patients, as many effective systemic psoriasis medications were previously available only as injections, which created inconvenience for some patients. The introduction of oral therapy may improve patient adherence to treatment and simplify its use at home without the need for injections. The MHRA's decision was made following an assessment of clinical trial data confirming the drug's efficacy and acceptable safety profile. The regulator noted that the new medication meets quality standards established for drugs approved for use in the United Kingdom. Dermatology specialists welcome the expansion of therapeutic options for psoriasis patients, emphasizing that the disease significantly reduces quality of life and requires an individualized approach to treatment. The drug is expected to be included in clinical guidelines and become available through the healthcare system following completion of necessary administrative procedures.